Agile 3+
Identification of advanced fibrosis in MASLD patients.
Learn more
Agile 4
Identification of cirrhosis in patients with MASLD.
Agile 4 utilizes FibroScan®-based Biomarkers.
Agile 4 Target
Cirrhosis is a leading cause of mortality worldwide.
Identifying cirrhosis early in patients helps to proactively manage the disease through screenings for liver-related complications such as hepatocellular carcinoma and esophageal varices.
Agile 4 Construction
Agile 4 combines LSM by VCTE™ with easily accessible blood biomarkers (AST, ALT, Platelets) to help in the identification of cirrhosis in MASLD patients to properly identify patients to start HCC and portal hypertension screening.
Formula
Agile 4 Performance
High clinical performances demonstrated in large external validation cohorts from different geographical origins.
Peer reviewed paper under submission
Sanyal et al., Enhanced diagnosis of advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease patients with FibroScan®-based Agile scores.
Agile 4: tried and trusted
Agile 4 and Agile 3+ well predict the occurrence of liverrelated events in patients with MASLD. Particularly, rule-in cut-offs of both scores better identify at-risk patients than LSM alone. These results demonstrate the interest of those scores in the identification of patients requiring hepatocellular carcinoma and esophageal varices screening.
A novel noninvasive score including LSM by VCTE™ and routine clinical parameters improves the identification of cirrhosis among patients with MASLD and may reduce the necessity of liver biopsy in this patient population.
All our solutions come with a dedicated support
From installation, to training and local support, we provide you with the highest quality of services.
Agile 4 Score Calculator is a registered class 1 device (FDA). Agile 4 Score Calculator is intended to compute the Fast score.
Agile 4 Score Calculator was developed based on pools of cohorts and are published in peer-reviewed literature. It is taken from clinical literature and utilize proprietary FibroScan measurements in their execution. While these scores are about specific medical and health issues, Echosens does not represent them as substitutes for, or replacements of personalized medical advice, or to be used as the sole basis for making individualized medical or health-related decisions.
*MASLD/MASH : formerly knowed as NAFLD/NASH
